Press Releases May 6, 2026 08:30 AM

Upexi Provides Periodic Update to its Share Repurchase Program

Upexi Updates Progress on $50 Million Share Repurchase Program to Enhance Shareholder Value

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
UPXI

Upexi, Inc., a Solana-focused digital asset treasury and consumer brands company, provided an update on its $50 million authorized share repurchase program announced in November 2025. As of May 5, 2026, the company has repurchased approximately 2.89 million shares, spending around $2 million, leaving over $47 million available for future repurchases. Management will continue to use this program to maximize shareholder value and will provide periodic updates.

Upexi Provides Periodic Update to its Share Repurchase Program
UPXI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Upexi has repurchased 2.89 million shares since program inception, spending about $2 million against the $50 million authorization.
  • The company focuses on accumulating Solana cryptocurrency and operates both in digital assets and consumer product sectors.
  • Management plans ongoing share repurchases and periodic disclosures to enhance shareholder value.

TAMPA, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ: UPXI) (“Upexi” or the “Company”), a leading Solana-focused digital asset treasury company and consumer brands owner, provided an update to the $50,000,000 authorized share repurchase program, previously announced on November 13, 2025.

Year-to-Date Share Repurchases

Trade monthNumber of common shares purchasedAverage price per share excluding fees Consideration excluding fees January 2026- $- $-February 20261,637,500$0.76 $1,246,450.70March 2026840,561$0.87 $728,230.80April 2026- $- $-Total2,478,061$ 0.80 $1,974,681.50      

As of May 5, 2026, the Company has repurchased a total of 2,894,287 shares of the Company’s common stock and has $47,226,036 remaining on its share repurchase program. Management will provide periodic updates to the share repurchase program through press releases and annual and quarterly financial reports.

Management will continue to use the share repurchase program and other available tools to maximize shareholder value.

About Upexi, Inc.
Upexi, Inc. (Nasdaq: UPXI) is a leading digital asset treasury company, where it aims to acquire and hold as much Solana (SOL) as possible in a disciplined and accretive fashion. In addition to benefiting from the potential price appreciation of Solana, the cryptocurrency of the leading high-performance blockchain, Upexi utilizes three key value accrual mechanisms in intelligent capital issuance, staking, and discounted locked token purchases. The Company operates in a risk-prudent fashion to position itself for any market environment and to appeal to investors of all kinds, and it currently holds roughly 2.4 million SOL. Upexi also continues to be a brand owner specializing in the development, manufacturing, and distribution of consumer products. Please see www.upexi.com for more information.

Follow Upexi on X - https://x.com/upexitreasury
Follow CEO, Allan Marshall, on X - https://x.com/upexiallan
Follow CSO, Brian Rudick, on X - https://x.com/thetinyant

Company Contact
Brian Rudick, Chief Strategy Officer
(203) 442-5391
brian.rudick@upexi.com

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Upexi@KCSA.com


Risks

  • The value of Upexi's holdings is exposed to the price volatility of Solana and digital assets, impacting treasury asset valuations and investor sentiment.
  • Share repurchases reduce cash reserves that could otherwise be used for operational or investment purposes, potentially impacting growth.
  • The overall cryptocurrency market environment remains uncertain and may affect Upexi's financial performance and stock price.

More from Press Releases

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc. Jun 15, 2026 Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform Jun 15, 2026 QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers Jun 15, 2026 Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 Jun 15, 2026 Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing Jun 15, 2026